Toggle Dropdown
Announcements
Projects
Welcome guest
Log in
Loading
Loading...
https://www.targetedonc.com/view/fda-grants-fast-track-designation-to-novel-tkk1-therapy-for-er-her2--advanced-breast-cancer
0
0
FDA Grants Fast Track Designation to Novel TKK1 Therapy for ER+/HER2- Advanced Breast Cancer - Targeted Oncology
+ 106 more
1/10/23 at 8:23pm
Organization
Targetedonc.com
Author
Nichole Tucker
Details
42 words
Summarize
Cancer
Health
Health Foundations & Medical Research
FDA Grants Fast Track Designation
Novel TKK1 Therapy for ER+
FDA
CFI-402257
The investigational drug, CFI-402257, has earned the FDA’s attention for promising preclinical results, and is now under investigation in a phase 1 study.
Show more
Create an account
or
login
to join the discussion
Modal title
...
Profile
Loading profile
Loading...